Dr. Greenbaum collaborates with industry partners to test new T1D therapeutics. These collaborations often involve multi-site phase 2 and phase 3 randomized clinical trials with the goal of understanding the efficacy of new therapies. A few of these collaborations include:
- Golimumab: Completed phase 2 multi-site randomized “TIGER” trial that demonstrated golimumab can preserve insulin secretion after diagnosis
- Teplizumab: Completed phase 3 multi-site randomized “PROTECT” trial, results expected in 2023
Additional Research Projects
Discover more research projects from the
Greenbaum Lab.
Experimental Medicine Unit studies at BRI
Dr. Greenbaum works with the Experimental Medicine Unit (EMU) at BRI to understand the biology behind experimental therapies. Most of these studies focus on type 1 diabetes.
Immune Tolerance Network (ITN) clinical trials in type 1 diabetes
In collaboration with the Immune Tolerance Network, our group conducts studies to understand the ways T1D therapies promote immune tolerance and to identify biomarkers associated with immune tolerance.
TrialNet clinical trials in those at risk of type 1 diabetes
We are deeply engaged in TrialNet studies and science, including our ongoing Pathway to Prevention trial that screens family member of T1D patients for T1D risk and the successful Teplizumab Prevention Trial.
